At this year’s AIBC conference, surgeons from UCSF, Allegheny Health Network and the University of Manchester NHS Trust came together to share their experiences and supporting data, to show how easily achievable this now is with the Sentimag® platform.
Read on to see the highlights from the huge iBRA-Net data set comparing 1,000 Magseed placements with 1,000 guidewires, how Magtrace is creating several exciting new opportunities for sentinel lymph node biopsy, and why combining both is providing the most dependable solution for Targeted Axillary Dissection.
To kick off proceedings, Mr Rajiv Dave shared the findings from the iBRA-Net study, which aimed to look at whether Magseed could be a viable long-term alternative to guidewires, considering factors such as re-excision rates, ease of placement and operating room time.
In these results, he explains how across the 126 registered collaborators, they found that the Magseed was successfully localised in 98.36% of cases (despite many users being new to the technology), it was easy to use and allowed for earlier surgical start times. This allows for more patients to be seen in a day.
“Particularly for multifocal lesions, bracketing and big oncoplastic surgeries, that [Magseed] has been very helpful”
ASBrS Past President, Jill Dietz, MD FACS, was the first person to use Magtrace for sentinel lymph node biopsy in the US following it’s FDA approval, so it’s fair to say she’s well experienced with the technology.
In this talk, she uncovered the issues with the current gold standard, such as availability and potential surgical complications and explained how the long injection window of Magtrace provides more flexibility while being non-inferior to the standard method.
Dr Dietz also discussed the initial data from her first 190 cases, including 25 patients who underwent the Delayed SLNB method (indicated for US patients undergoing mastectomy). Popularised by the SentiNOT study, this technique has shown that on average 80% of high-risk DCIS patients could be spared unnecessary axillary surgery with Magtrace.
“I’m passionate about high value care - anything that can give your patient an excellent outcome and is cost effective, which is why I’m presenting this to you here today”
Professor Michael Alvarado has been a huge advocate for Magseed and Magtrace for many years. In his talk, he explained how the emergence of Targeted Axillary Dissection has allowed for the perfect opportunity to use both in conjunction, without the need for multiple systems.
From providing a small enough marker that won’t migrate, a tracer that is proven to average 2.4 nodes per surgery and over 1,000 patients in Sentimag-led TAD clinical data, Dr Alvarado explained why it’s the method he trusts to deliver the best results.
“We wanted to have control over the injection of the mapping agent… and have it all [TAD] in one package”
To bring the session to an end, the panel took questions on several topics, including how to work with administration to bring in new technology, working with non-metallic retractors and most importantly how we provide the very best patient experience.
We’d like to thank all of the panellists that took part in the session, as well as our fantastic moderators, Mr Bruce Mann and Emilia Dauway, MD – plus all those who attended and got involved in the discussion.